Jakub Fichna
Jakub Fichna
Medical University of Lodz, Poland
Geverifieerd e-mailadres voor umed.lodz.pl - Homepage
Geciteerd door
Geciteerd door
Opioid receptors and their ligands
A Janecka, J Fichna, T Janecki
Current topics in medicinal chemistry 4 (1), 1-17, 2004
The endomorphin system and its evolving neurophysiological role
J Fichna, A Janecka, J Costentin, JC Do Rego
Pharmacological reviews 59 (1), 88-123, 2007
Synthesis of target-specific radiolabeled peptides for diagnostic imaging
J Fichna, A Janecka
Bioconjugate chemistry 14 (1), 3-17, 2003
The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases
A Piechota-Polanczyk, J Fichna
Naunyn-Schmiedeberg's archives of pharmacology 387 (7), 605-620, 2014
Distribution, function and physiological role of melatonin in the lower gut
CQ Chen, J Fichna, M Bashashati, YY Li, M Storr
World journal of gastroenterology: WJG 17 (34), 3888, 2011
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives
M Sobczak, M Sałaga, MA Storr, J Fichna
Journal of gastroenterology 49 (1), 24-45, 2014
Brain-gut interactions in IBS
J Fichna, M Storr
Frontiers in Pharmacology 3, 127, 2012
The role of morphine in regulation of cancer cell growth
K Gach, A Wyrębska, J Fichna, A Janecka
Naunyn-Schmiedeberg's archives of pharmacology 384 (3), 221, 2011
Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease
A Wasilewski, M Zielińska, M Storr, J Fichna
Inflammatory bowel diseases 21 (7), 1674-1682, 2015
Natural and synthetic α-methylenelactones and α-methylenelactams with anticancer potential
A Janecka, A Wyrębska, K Gach, J Fichna, T Janecki
Drug Discovery Today 17 (11-12), 561-572, 2012
Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment
O Nitzan, M Elias, B Chazan, R Raz, W Saliba
World journal of gastroenterology: WJG 19 (43), 7577, 2013
Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases
M Sobczak, A Fabisiak, N Murawska, E Wesołowska, P Wierzbicka, ...
Pharmacological Reports 66 (5), 766-775, 2014
Enzymatic degradation of endomorphins
A Janecka, R Staniszewska, K Gach, J Fichna
Peptides 29 (11), 2066-2073, 2008
Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ‐opioid and cannabinoid receptors
J Fichna, R Schicho, CN Andrews, M Bashashati, M Klompus, DM McKay, ...
Neurogastroenterology & Motility 21 (12), 1326-e128, 2009
Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors
J Fichna, M Dicay, K Lewellyn, A Janecka, JK Zjawiony, ...
Inflammatory bowel diseases 18 (6), 1137-1145, 2012
A randomized clinical trial of berberine hydrochloride in patients with diarrhea‐predominant irritable bowel syndrome
C Chen, C Tao, Z Liu, M Lu, Q Pan, L Zheng, Q Li, Z Song, J Fichna
Phytotherapy research 29 (11), 1822-1827, 2015
Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH)
M Sałaga, A Mokrowiecka, PK Zakrzewski, A Cygankiewicz, E Leishman, ...
Journal of Crohn's and Colitis 8 (9), 998-1009, 2014
Effects of berberine in the gastrointestinal tract—a review of actions and therapeutic implications
C Chen, Z Yu, Y Li, J Fichna, M Storr
The American Journal of Chinese Medicine 42 (05), 1053-1070, 2014
Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice
J Fichna, A Janecka, M Piestrzeniewicz, J Costentin, JC do Rego
Neuropsychopharmacology 32 (4), 813-821, 2007
Polyphenols as mitochondria-targeted anticancer drugs
S Gorlach, J Fichna, U Lewandowska
Cancer Letters 366 (2), 141-149, 2015
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20